CreativeOne Wealth LLC Acquires New Holdings in Insulet Co. (NASDAQ:PODD)

CreativeOne Wealth LLC acquired a new stake in shares of Insulet Co. (NASDAQ:PODD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 887 shares of the medical instruments supplier’s stock, valued at approximately $206,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in PODD. Blue Trust Inc. increased its holdings in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Insulet during the second quarter valued at approximately $32,000. Venturi Wealth Management LLC increased its holdings in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 133 shares during the last quarter. UMB Bank n.a. increased its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 81 shares during the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its holdings in Insulet by 159.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 254 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 156 shares during the last quarter.

Insulet Stock Performance

Shares of Insulet stock opened at $269.66 on Wednesday. The firm’s fifty day simple moving average is $244.95 and its 200-day simple moving average is $214.95. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market capitalization of $18.91 billion, a price-to-earnings ratio of 46.17, a PEG ratio of 4.07 and a beta of 1.21.

Analyst Upgrades and Downgrades

A number of analysts have commented on PODD shares. Piper Sandler upped their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Canaccord Genuity Group increased their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Morgan Stanley increased their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price objective for the company. Finally, Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.